iScience (Feb 2021)
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
- Sreelekshmy Mohandas,
- Pragya D. Yadav,
- Anita Shete-Aich,
- Priya Abraham,
- Krishna Mohan Vadrevu,
- Gajanan Sapkal,
- Chandrashekhar Mote,
- Dimpal Nyayanit,
- Nivedita Gupta,
- Vellimedu Kannappa Srinivas,
- Manoj Kadam,
- Abhimanyu Kumar,
- Triparna Majumdar,
- Rajlaxmi Jain,
- Gururaj Deshpande,
- Savita Patil,
- Prasad Sarkale,
- Deepak Patil,
- Raches Ella,
- Sai D. Prasad,
- Sharda Sharma,
- Krishna M. Ella,
- Samiran Panda,
- Balram Bhargava
Affiliations
- Sreelekshmy Mohandas
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Pragya D. Yadav
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India; Corresponding author
- Anita Shete-Aich
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Priya Abraham
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Krishna Mohan Vadrevu
- Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India
- Gajanan Sapkal
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Chandrashekhar Mote
- Department of Veterinary Pathology, Krantisinh Nana Patil College of Veterinary Science, Shirwal, Maharashtra 412801, India
- Dimpal Nyayanit
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Nivedita Gupta
- Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India
- Vellimedu Kannappa Srinivas
- Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India
- Manoj Kadam
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Abhimanyu Kumar
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Triparna Majumdar
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Rajlaxmi Jain
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Gururaj Deshpande
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Savita Patil
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Prasad Sarkale
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Deepak Patil
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Raches Ella
- Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India
- Sai D. Prasad
- Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India
- Sharda Sharma
- Indian Council of Medical Research-National Institute of Virology, Sus Road, Pashan, Pune, Maharashtra 411021, India
- Krishna M. Ella
- Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana 500 078, India
- Samiran Panda
- Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India
- Balram Bhargava
- Indian Council of Medical Research,V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi 110029, India
- Journal volume & issue
-
Vol. 24,
no. 2
p. 102054
Abstract
Summary: The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed the immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidates BBV152A, BBV152B, and BBV152C in Syrian hamsters. Three dose vaccination regimes with vaccine candidates induced significant titers of SARS-CoV-2-specific IgG and neutralizing antibodies. BBV152A and BBV152B vaccine candidates remarkably generated a quick and robust immune response. Post-SARS-CoV-2 infection, vaccinated hamsters did not show any histopathological changes in the lungs. The protection of the hamster was evident by the rapid clearance of the virus from lower respiratory tract, reduced virus load in upper respiratory tract, absence of lung pathology, and robust humoral immune response. These findings confirm the immunogenic potential of the vaccine candidates and further protection of hamsters challenged with SARS-CoV-2. Of the three candidates, BBV152A showed the better response.